One Global Service Provider up 8% on acquiring two diagnostics firms via share swap

According to the main letter to BSE (pages 1–3) and Annexure C1 and C2:

• One Global will acquire 51% equity stake in Matrix Labs Diagnocare Private Limited (MLDPL).
• It will also acquire 51% equity stake in Matrix Labs Private Limited (MLPL).
• For MLDPL, the company proposes to buy 13,321 equity shares, representing 51% of its total issued, subscribed and paid‑up equity share capital.
• For MLPL, it will acquire 2,550 equity shares, again representing 51% of the total issued, subscribed and paid‑up equity share capital.

The filing positions both targets squarely in the diagnostics value chain:

• MLDPL (Annexure C1, page 6) operates in the In‑Vitro Diagnostics (IVD), Medical Diagnostics and Healthcare industry, offering diagnostic solutions across immunology, HPLC, clinical automation, microbiology, hematology, biochemistry, homeostasis and point‑of‑care testing.
• MLPL (Annexure C2, page 8) belongs to the Medical Equipment and In‑Vitro Diagnostics (IVD) industry, focused on development, manufacture and supply of IVD kits, diagnostic reagents, instruments and analysers, including CLIA, clinical chemistry and FIA‑based solutions.

This gives One Global both a front‑end diagnostics platform (MLDPL) and a manufacturing/R&D‑heavy supplier (MLPL), which the company explicitly describes as a way to “expand its diagnostic product and technology offerings” and “achieve strategic and operational synergies”.

A key reason the stock appears to have rerated is the way One Global is paying for the acquisitions.

On pages 1–3 and in Annexure E (pages 14–15), the company states that:

• The consideration for MLDPL is Rs. 35,97,81,800.
• The consideration for MLPL is Rs. 3,56,35,320.
• The total consideration thus aggregates to Rs. 39,54,17,120.
• This will be discharged entirely via issuance and allotment of equity shares of One Global on a preferential basis for consideration other than cash, under a share swap arrangement.

The preferential issue details are clear:

• One Global will issue 7,15,040 fully paid‑up equity shares.
• Each share has a face value of Rs. 10 and an issue price of Rs. 553 per share, including premium (Annexure E, point 4(c)).
• The issue price “shall not be less than the price determined in accordance with Chapter V” of the SEBI ICDR Regulations.

The allotment is split as follows (pages 2, 10, 12 and 14–15):

• For MLDPL: 6,01,760 equity shares to Mr. Suresh and 48,840 equity shares to Ms. Nithya S.
• For MLPL: 64,440 equity shares to Mr. Suresh.

Post‑issue, Annexure E (page 15) shows that:

• Mr. Suresh will hold 6,66,200 equity shares, equivalent to 3.29% of One Global.
• Ms. Nithya S will hold 48,840 equity shares, equivalent to 0.24%.

For existing shareholders, this means equity dilution, but the filing quantifies it as relatively modest in percentage terms for the new allottees. Because the deal is non‑cash and priced at Rs. 553 per share, the market appears to be reading it as an asset‑light way to bolt on scale in a high‑growth healthcare niche.

The annexures also give a sense of what One Global is buying into.

For MLDPL (Annexure C1, page 6–7):

• Turnover as on 31 March 2025 is disclosed as Rs. 171.30 Crore.
• The company was incorporated on 15 September 2023.

For MLPL (Annexure C2, page 8–9):

• Turnover as on 31 March 2025 is Rs. 8.92 Crore.
• Prior years’ turnover is Rs. 2.42 Crore for 2022‑23 and Rs. 4.91 Crore for 2023‑24.
• Date of incorporation is 30 January 2014.

The filing does not disclose profitability, margins or valuation multiples for either entity, so investors cannot yet assess earnings accretion or return metrics from the document alone. However, the turnover numbers – especially the Rs. 171.30 Crore for MLDPL – help explain why the street might be willing to look past the dilution and focus on potential scale benefits.

Both Annexure C1 and C2 spell out the objectives of the acquisitions in similar language:

• To strengthen the Company’s presence in the healthcare, medical diagnostics and IVD sector/segment.
• To expand its diagnostic product and technology offerings.
• To leverage the targets’ capabilities – including Matrix Labs’ R&D and manufacturing capabilities in the case of MLPL.
• To pursue strategic and operational synergies and “enhance long‑term shareholder value”.

The company also notes (Annexure C1 and C2, point 2) that these are not related party transactions, and that the promoter/promoter group/group companies “do not have any interest in the entity being acquired”. That clarity on governance and arm’s‑length dealing can be another incremental positive for investors.

Alongside the acquisitions, the board has approved a sizeable increase in authorised share capital (page 3 and Annexure F, page 16):

• From Rs. 25,05,00,000, divided into 2,50,50,000 equity shares of Rs. 10 each.
• To Rs. 50,00,00,000, divided into 5,00,00,000 equity shares of Rs. 10 each.

The capital clause in the Memorandum of Association will be altered accordingly.

While the filing does not explicitly say this is to fund further acquisitions or growth, the timing – alongside a preferential issue for two sizeable deals – suggests the company wants headroom for future equity issuance. The market may be interpreting this as a signal that One Global intends to build a larger healthcare and diagnostics platform over time.

The same board meeting also covered more standard corporate housekeeping (pages 1, 4–5):

• Appointment of M/s. S D P M & Co. (FRN:126741W) as statutory auditors for a second five‑year term, from the conclusion of the 34th AGM to the conclusion of the 39th AGM.
• Appointment of M/s. Valawat & Associates (FRN: 434660) as internal auditors for FY 2026‑27, following the resignation of the previous internal auditor on 14 August 2026.
• Convening of the 34th AGM on 29 September 2026 through video conferencing/other audio‑visual means.

These items are unlikely to have driven the share‑price move on their own, but they round out the governance picture.

Despite the strong price reaction, there are notable gaps in the disclosure from an investor‑analysis perspective:

• No profit or margin numbers are provided for MLDPL or MLPL.
• There is no guidance on whether the acquisitions will be earnings accretive or dilutive in the near term.
• The filing does not disclose any integration plan, cost synergies, or capex commitments post‑acquisition.

Given those omissions, the 8.0% move in the stock to Rs 542 likely reflects the market’s enthusiasm for the strategic direction – a deeper push into diagnostics via a non‑cash share swap – rather than a detailed assessment of near‑term financial impact. Further clarity on profitability and integration will be needed in subsequent communications to fully justify the rerating.

For now, the message from the tape is that investors are willing to back One Global’s bet on building a broader healthcare and diagnostics platform, even at the cost of some dilution.